Virbac S.A. stock (FR0000031577): animal health specialist after strong 2024 figures and cautious 2025 outlook

Virbac S.A. has reported solid growth for 2024 and presented a cautious but positive outlook for 2025. How is the French animal health group positioned, and what could matter next for US investors watching this niche player?

Virbac S.A. has drawn fresh attention from investors after reporting higher revenue and profits for 2024 and outlining a cautious but positive outlook for 2025 in its recent results and annual report, underscoring the resilience of its animal health portfolio across companion animals and livestock, according to the company’s publications and Euronext filings in early 2025, as reported by Virbac investor information as of 03/20/2025 and Euronext data as of 03/21/2025.

As of: 05/15/2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Virbac
• Sector/industry: Animal health, veterinary pharmaceuticals
• Headquarters/country: Carros, France
• Core markets: Global companion animal and livestock markets
• Key revenue drivers: Parasite treatments, vaccines, dermatology and nutrition for animals
• Home exchange/listing venue: Euronext Paris (ticker: VIRP)
• Trading currency: EUR

Virbac S.A.: core business model

Virbac focuses exclusively on animal health, with a portfolio of veterinary medicines, vaccines, parasiticides and nutritional products for both companion animals and farm animals. The company generates most of its revenue from prescription and over-the-counter products sold through veterinarians and specialty distributors, according to its latest annual report published in March 2025 for the 2024 financial year, as highlighted by Virbac annual report as of 03/20/2025.

The group operates a decentralized model with regional subsidiaries covering Europe, the Americas, Asia-Pacific and emerging markets, supplying local veterinary clinics and farm operators. It competes with large diversified players in animal health but positions itself as a focused specialist with a wide range of species-specific solutions, according to the same 2024 report and related investor presentations published in March 2025, as summarized by Virbac regulated information as of 03/25/2025.

Virbac’s business model aims for balanced exposure across species and regions, which can reduce reliance on any single market. Companion animal products such as flea and tick treatments, dermatology drugs and vaccines provide higher margins, while livestock products in areas such as ruminant and swine health offer volume and diversification, according to the company’s segmentation comments in its 2024 results communication released in March 2025, as referenced by Virbac financial releases as of 03/21/2025.

Main revenue and product drivers for Virbac S.A.

In its 2024 full-year results published in March 2025, Virbac reported an increase in annual revenue compared with 2023, driven by growth across several regions and in key companion animal franchises. The company highlighted strong performance in dermatology, internal and external parasiticides and vaccines for dogs and cats, according to its earnings documentation for 2024 released in March 2025, as noted by Virbac results presentation as of 03/21/2025.

Livestock products also contributed, with Virbac pointing to steady demand in ruminant and swine health solutions across Latin America and parts of Asia. However, the company indicated that some farm animal markets remained mixed due to price pressure and changing herd dynamics, according to commentary in its 2024 activity report published on March 20, 2025, as captured by Virbac activity report 2024 as of 03/20/2025.

Profitability improved in 2024, supported by operating leverage on higher volumes and cost discipline, even as Virbac continued to invest in research and development. The company reported an increase in operating profit and net income versus 2023, while confirming that R&D spending remained a mid- to high-single-digit percentage of sales to support its innovation pipeline, according to its 2024 results release dated March 21, 2025, as reported by Virbac full-year 2024 results as of 03/21/2025.

The group’s portfolio includes long-established brands as well as newer products resulting from recent development programs. In companion animals, the emphasis has been on parasiticides, dermatology and innovative formulations that improve ease of administration for pet owners. In livestock, Virbac’s range covers vaccines and therapeutics designed to support herd health, productivity and disease prevention in cattle, swine and poultry, according to its 2024 product and pipeline overview published in March 2025, as outlined by Virbac share information as of 03/22/2025.

Conclusion

Virbac S.A. enters 2025 with momentum from a year of revenue and profit growth, supported by diversified exposure to companion animals and livestock and an ongoing commitment to R&D. The company’s focused animal health model and global reach position it in an expanding market, although competitive pressures, regulatory requirements and cyclical farm demand remain important factors for investors to monitor. For US investors tracking international animal health names alongside domestic peers, Virbac offers a specialized European perspective on long-term trends in pet care and livestock productivity without implying any particular investment action.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.